Distributes equipment, medical devices, and reagents to healthcare systems. Provides products and solutions for biomedical research and laboratory equipment. Now — the numbers.
This is an established company with proven profits.
Average growth of 7% a year over the last 4 years. Every year shown ended in profit.
The gap is $409.0M. In times of high interest rates, a gap like that can squeeze a company.
The market pays 31.9× for every dollar of annual profit — around what a business like this usually costs.
No analyst target is on record for this company.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
R&D Investment: Spending on future research is low.
An investor who bought at the very peak is down 63% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
It pays out $0.16 per share each year — regular cash for whoever holds the stock.
The share set aside for the future is small; the pace of new ideas may slow. Council score: 2/10.
Getting in and out without moving the price could prove difficult. Council score: 2/10.
Since the drop from its peak, buyer appetite hasn’t come back. Council score: 2/10.
We don’t have a report card for this stock yet — the data isn’t mature enough to grade. No grade is information too: it means the evidence is thin.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: the revenue breakdown.